Literature DB >> 27899389

High dose rivastigmine in the symptom management of Lewy body dementia.

Joseph Marwan Nour1, Leonidas Chouliaras2, Lilian Hickey3.   

Abstract

A man presented in late 2004 at the age of 65 with a decline in memory. He was diagnosed with Lewy body dementia and started on 3 mg rivastigmine a day, which made a marked clinical improvement. He lived with the illness for 10 years, over which time the dose of acetylcholinesterase inhibitors (ChEI) he took rose to two 9.5 mg rivastigmine patches and 7.5 mg donepezil, significantly above British National Formulary (BNF) limits. He demonstrated clear clinical response to ChEI and showed improvements in alertness and functioning. He did not exhibit life-threatening cardiac side effects and his death in 2014 was not related to the ChEI. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27899389      PMCID: PMC5174755          DOI: 10.1136/bcr-2016-217240

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  6 in total

1.  Improvement of cognitive dysfunction with high-dose rivastigmine.

Authors:  Antonios M Politis; Christos Theleritis; Maria Passa; Antonios Maillis; George N Papadimitriou
Journal:  Psychosomatics       Date:  2010 Jan-Feb       Impact factor: 2.386

2.  Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.

Authors:  Martin R Farlow; Stephen Salloway; Pierre N Tariot; Jane Yardley; Margaret L Moline; Qin Wang; Elimor Brand-Schieber; Heng Zou; Timothy Hsu; Andrew Satlin
Journal:  Clin Ther       Date:  2010-07       Impact factor: 3.393

3.  Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.

Authors:  P J Reading; A K Luce; I G McKeith
Journal:  Mov Disord       Date:  2001-11       Impact factor: 10.338

4.  Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study.

Authors:  I McKeith; T Del Ser; P Spano; M Emre; K Wesnes; R Anand; A Cicin-Sain; R Ferrara; R Spiegel
Journal:  Lancet       Date:  2000-12-16       Impact factor: 79.321

5.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Authors:  S L Rogers; M R Farlow; R S Doody; R Mohs; L T Friedhoff
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

6.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

Authors:  M Rösler; R Anand; A Cicin-Sain; S Gauthier; Y Agid; P Dal-Bianco; H B Stähelin; R Hartman; M Gharabawi
Journal:  BMJ       Date:  1999-03-06
  6 in total
  1 in total

1.  Pharmacophore mapping of the crucial mediators of acetylcholinesterase and butyrylcholinesterase dual inhibition in Alzheimer's disease.

Authors:  Fatima Y Adeowo; Ahmed A Elrashedy; Murtala A Ejalonibu; Isiaka A Lawal; Monsurat M Lawal; Hezekiel M Kumalo
Journal:  Mol Divers       Date:  2022-01-24       Impact factor: 3.364

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.